Wachter R M, Luce J M, Safrin S, Berrios D C, Charlebois E, Scitovsky A A
Medical Service, San Francisco General Hospital Medical Center.
JAMA. 1995 Jan 18;273(3):230-5.
To determine the costs and outcomes associated with intensive care unit (ICU) admission for patients with acquired immunodeficiency syndrome (AIDS)-related Pneumocystis carinii pneumonia (PCP), and severe respiratory failure.
Survival and cost-effectiveness analysis.
A large municipal teaching hospital serving an indigent population.
Consecutive patients intubated and mechanically ventilated for AIDS, PCP, and respiratory failure from 1981 through 1991 (n = 113). The cohort was separated into three groups for analysis: patients admitted to the ICU in 1981 through 1985 (era I, n = 43), those admitted in 1986 through 1988 (era II, n = 33), and those admitted in 1989 through 1991 (era III, n = 37).
Hospital charges and survival time; cost per year of life saved, using a zero-cost, zero-life assumption.
Twenty-eight (25%) of the 113 patients mechanically ventilated for PCP and respiratory failure survived to hospital discharge: six (14%) of 43 in era I, 13 (39%) of 33 in era II, and nine (24%) of 37 in era III (P = .04). Post-ICU admission charges averaged $57,874 for the entire cohort, remaining relatively stable across the three eras. Cost of care for survivors was significantly more expensive than for those dying before discharge. The cost of ICU admission and subsequent hospitalization averaged $174,781 per year of life saved; $305,795 in era I, $94,528 in era II, and $215,233 in era III. Improved survival rates and shorter lengths of ICU stay led to the improved cost-effectiveness in era II, while the opposite trends resulted in worsening cost-effectiveness in recent years. The strongest predictors of hospital mortality in era III were low CD4 cell counts on hospital admission and the development of pneumothorax during mechanical ventilation.
The cost-effectiveness of intensive care for patients with PCP and severe respiratory failure improved during the first 8 years of the AIDS epidemic but fell in recent years such that it is now below that of many accepted medical interventions.
确定获得性免疫缺陷综合征(AIDS)相关卡氏肺孢子虫肺炎(PCP)及严重呼吸衰竭患者入住重症监护病房(ICU)的成本及预后。
生存及成本效益分析。
一家为贫困人口服务的大型市级教学医院。
1981年至1991年因AIDS、PCP及呼吸衰竭接受气管插管和机械通气的连续患者(n = 113)。该队列分为三组进行分析:1981年至1985年入住ICU的患者(时期I,n = 43),1986年至1988年入住的患者(时期II,n = 33),以及1989年至1991年入住的患者(时期III,n = 37)。
医院收费及生存时间;采用零成本、零生命假设计算每挽救一年生命的成本。
113例因PCP及呼吸衰竭接受机械通气的患者中有28例(25%)存活至出院:时期I的43例中有6例(14%),时期II的33例中有13例(39%),时期III的37例中有9例(24%)(P = 0.04)。整个队列入住ICU后的收费平均为57,874美元,在三个时期相对稳定。存活患者的护理成本显著高于出院前死亡患者。入住ICU及后续住院的成本平均为每挽救一年生命174,781美元;时期I为305,795美元,时期II为94,528美元,时期III为215,233美元。时期II存活率提高及ICU住院时间缩短导致成本效益改善,而近年来相反的趋势导致成本效益恶化。时期III医院死亡率最强的预测因素是入院时CD4细胞计数低及机械通气期间发生气胸。
在AIDS流行的前8年,PCP及严重呼吸衰竭患者重症监护的成本效益有所改善,但近年来有所下降,目前已低于许多公认的医疗干预措施。